These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31585169)

  • 1. The NCATS Pharmaceutical Collection: a 10-year update.
    Huang R; Zhu H; Shinn P; Ngan D; Ye L; Thakur A; Grewal G; Zhao T; Southall N; Hall MD; Simeonov A; Austin CP
    Drug Discov Today; 2019 Dec; 24(12):2341-2349. PubMed ID: 31585169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays.
    Lee JA; Shinn P; Jaken S; Oliver S; Willard FS; Heidler S; Peery RB; Oler J; Chu S; Southall N; Dexheimer TS; Smallwood J; Huang R; Guha R; Jadhav A; Cox K; Austin CP; Simeonov A; Sittampalam GS; Husain S; Franklin N; Wild DJ; Yang JJ; Sutherland JJ; Thomas CJ
    PLoS One; 2015; 10(7):e0130796. PubMed ID: 26177200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.
    Huang R; Southall N; Wang Y; Yasgar A; Shinn P; Jadhav A; Nguyen DT; Austin CP
    Sci Transl Med; 2011 Apr; 3(80):80ps16. PubMed ID: 21525397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCATS Inxight Drugs: a comprehensive and curated portal for translational research.
    Siramshetty VB; Grishagin I; Nguyễn ÐT; Peryea T; Skovpen Y; Stroganov O; Katzel D; Sheils T; Jadhav A; Mathé EA; Southall NT
    Nucleic Acids Res; 2022 Jan; 50(D1):D1307-D1316. PubMed ID: 34648031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The National Center for Advancing Translational Sciences' Intramural Training Program and Fellow Career Outcomes.
    Haynes B; Brimacombe K; Hare C; Faupel-Badger J
    CBE Life Sci Educ; 2020 Dec; 19(4):ar51. PubMed ID: 33001768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NIH center struggles to speed new therapies.
    Kaiser J
    Science; 2019 Sep; 365(6460):1363. PubMed ID: 31604250
    [No Abstract]   [Full Text] [Related]  

  • 7. Battle over rare disease drug ensnares NIH.
    Wadman M
    Science; 2016 Oct; 354(6308):18-19. PubMed ID: 27846474
    [No Abstract]   [Full Text] [Related]  

  • 8. The NCATS Assay Guidance Manual programme: advancing the practice and rigour of preclinical translation.
    Markossian S; Brimacombe KR; Sittampalam GS; Grossman A; Coussens NP; Inglese J; Auld DS; Chin W; Austin CP; Hall MD
    Nat Rev Drug Discov; 2022 Dec; 21(12):863-864. PubMed ID: 36253455
    [No Abstract]   [Full Text] [Related]  

  • 9. Diversity, equity and inclusion actions from the NCATS Clinical and Translational Science awarded programs.
    Boulware LE; Vitale A; Ruiz R; Corbie G; Aguilar-Gaxiola S; Wilkins CH; Egede LE
    Nat Med; 2022 Sep; 28(9):1730-1731. PubMed ID: 35764682
    [No Abstract]   [Full Text] [Related]  

  • 10. Validating ADME QSAR Models Using Marketed Drugs.
    Siramshetty V; Williams J; Nguyễn ÐT; Neyra J; Southall N; Mathé E; Xu X; Shah P
    SLAS Discov; 2021 Dec; 26(10):1326-1336. PubMed ID: 34176369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates.
    Southan C; Williams AJ; Ekins S
    Drug Discov Today; 2013 Jan; 18(1-2):58-70. PubMed ID: 23159359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting Repurposing.
    Sharlow ER
    Assay Drug Dev Technol; 2016 Dec; 14(10):554-556. PubMed ID: 27982703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keeping It Clean: The Cell Culture Quality Control Experience at the National Center for Advancing Translational Sciences.
    Roth JS; Lee TD; Cheff DM; Gosztyla ML; Asawa RR; Danchik C; Michael S; Simeonov A; Klumpp-Thomas C; Wilson KM; Hall MD
    SLAS Discov; 2020 Jun; 25(5):491-497. PubMed ID: 32233736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational and experimental advances in drug repositioning for accelerated therapeutic stratification.
    Shameer K; Readhead B; Dudley JT
    Curr Top Med Chem; 2015; 15(1):5-20. PubMed ID: 25579574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repurposing FDA-approved drugs for anti-aging therapies.
    Snell TW; Johnston RK; Srinivasan B; Zhou H; Gao M; Skolnick J
    Biogerontology; 2016 Nov; 17(5-6):907-920. PubMed ID: 27484416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing of approved cardiovascular drugs.
    Ishida J; Konishi M; Ebner N; Springer J
    J Transl Med; 2016 Sep; 14():269. PubMed ID: 27646033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
    Cummings JL; Zhong K
    Expert Rev Clin Pharmacol; 2014 Mar; 7(2):161-5. PubMed ID: 24502586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomics-enabled drug repositioning and repurposing: insights from an IOM Roundtable activity.
    Power A; Berger AC; Ginsburg GS
    JAMA; 2014 May; 311(20):2063-4. PubMed ID: 24867009
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.